SCHEMBL22200786

SCHEMBL22200786

CC(C)n1c(=O)c(-c2cc(F)c(NSCC3CC(F)(F)C3)c(F)c2)nc2cnc(N)nc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 3/20 0.43
MTOR P42345 6/20 0.35
ALDH1A1 P00352 5/20 0.33
CYP1A2 P05177 5/20 0.33
HSD17B10 Q99714 5/20 0.33
CASP1 P29466 4/20 0.33
CASP7 P55210 4/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
CYP2D6 P10635 2/20 0.33
LMNA P02545 1/20 0.33
GLA P06280 2/20 0.33
CLK4 Q9HAZ1 2/20 0.33
USP2 O75604 1/20 0.33
HIF1A Q16665 1/20 0.33
PIK3CA P42336 4/20 0.32
TLR9 Q9NR96 1/20 0.32
TLR8 Q9NR97 1/20 0.32
TLR7 Q9NYK1 1/20 0.32
CYP3A4 P08684 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22200827 0.90 ERN1 (0.42) ERN1MTORALDH1A1CYP1A2HSD17B10
SCHEMBL22200823 0.89 ERN1 (0.45) ERN1MTORALDH1A1CYP1A2HSD17B10
SCHEMBL25035641 0.84 ERN1 (0.52) ERN1MTORALDH1A1CYP1A2HSD17B10
SCHEMBL22200658 0.83 ERN1 (0.44) ERN1MTORALDH1A1CYP1A2HSD17B10
SCHEMBL22200627 0.83 ERN1 (0.52) ERN1MTORALDH1A1CYP1A2HSD17B10
SCHEMBL22200826 0.82 ERN1 (0.39) ERN1MTORALDH1A1CYP1A2HSD17B10
SCHEMBL22200719 0.82 ERN1 (0.42) ERN1MTORALDH1A1CYP1A2HSD17B10
SCHEMBL22200788 0.81 USP2 (0.40) ERN1ALDH1A1CYP1A2HSD17B10CASP1
SCHEMBL22200635 0.81 ERN1 (0.39) ERN1ALDH1A1CYP1A2HSD17B10CASP1
SCHEMBL22200470 0.80 ERN1 (0.42) ERN1MTORALDH1A1CYP1A2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed